Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20
BW Businessworld

Dr Reddys Labs Launches Tecfidera Generic In US Market

The company's product is a therapeutic equivalent generic version of Biogen's Tecfidera delayed-release capsules, the Hyderabad-based drug firm said in a statement.

Photo Credit :

1465632012_6qcJyj_Pharma_Dr-reddy-870.jpg

Dr Reddy's Laboratories on Saturday said it has launched Dimethyl Fumarate delayed-release capsules, used to treat multiple sclerosis (MS), in the US market.

The company's product is a therapeutic equivalent generic version of Biogen's Tecfidera delayed-release capsules, the Hyderabad-based drug firm said in a statement.

According to IQVIA Health data, the Tecfidera brand and generic market had sales of around USD 3.8 billion (about Rs 28,000 crore) in the US for the most recent twelve months ending in June 2020. 

(PTI)


Tags assigned to this article:
dr reddys laboratories Tecfidera Generic us market